Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains

References

• Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe. 2010;7(6):440–451.
   PubMed Web of Science ®Google Scholar
• Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998;26(6):1418–1424.
   PubMed Web of Science ®Google Scholar
• de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353(25):2667–2672.
   PubMed Web of Science ®Google Scholar
• Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 1981;289(5796):373–378.
   PubMed Web of Science ®Google Scholar
• Jang YH, Seong BL. Cross-protective immune responses elicited by live attenuated influenza vaccines. Yonsei Med J. 2013;54(2):271–282.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Jama. 2003;289(2):179–186.
   PubMed Web of Science ®Google Scholar
• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–1300.
   PubMed Web of Science ®Google Scholar
• Paules C, Subbarao K. Influenza. Lancet. 2017;390(10095):697–708.
   PubMed Web of Science ®Google Scholar
• Kim P, Jang YH, Kwon SB, et al. Glycosylation of hemagglutinin and neuraminidase of influenza a virus as signature for ecological spillover and adaptation among influenza reservoirs. Viruses. 2018;10:4.
   Web of Science ®Google Scholar
• Shin WJ, Seong BL. Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery. Expert Opin Drug Discov. 2013;8(4):411–426.
   PubMed Web of Science ®Google Scholar
• Coughlan L, Palese P. Overcoming barriers in the path to a universal influenza virus vaccine. Cell Host Microbe. 2018;24(1):18–24.
   PubMed Web of Science ®Google Scholar
• Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature. 2008;451(7178):591–595.
   PubMed Web of Science ®Google Scholar
• Shtyrya YA, Mochalova LV, Bovin NV. Influenza virus neuraminidase: structure and function. Acta Naturae. 2009;1(2):26–32.
   PubMed Web of Science ®Google Scholar
• Kumar B, Asha K, Khanna M, et al. The emerging influenza virus threat: status and new prospects for its therapy and control. Arch Virol. 2018;163(4):831–844.
   PubMed Web of Science ®Google Scholar
• Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. Jama. 2006;295(8):891–894.
   PubMed Web of Science ®Google Scholar
• Valette M, Allard JP, Aymard M, et al. Susceptibilities to rimantadine of influenza A/H1N1 and A/H3N2 viruses isolated during the epidemics of 1988 to 1989 and 1989 to 1990. Antimicrob Agents Chemother. 1993;37(10):2239–2240.
   PubMed Web of Science ®Google Scholar
• Inoue M, Barkham T, Leo YS, et al. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours. Emerg Infect Dis. 2010;16(10):1633–1636.
   PubMed Web of Science ®Google Scholar
• Tandel K, Sharma S, Dash PK, et al. Oseltamivir-resistant influenza A(H1N1)pdm09 virus associated with high case fatality, India 2015. J Med Virol. 2018;90(5):836–843.
   PubMed Web of Science ®Google Scholar
• von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993;363(6428):418–423.
   PubMed Web of Science ®Google Scholar
• Omoto S, Speranzini V, Hashimoto T, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633.
   PubMedGoogle Scholar
• Watanabe K, Ishikawa T, Otaki H, et al. Structure-based drug discovery for combating influenza virus by targeting the PA-PB1 interaction. Sci Rep. 2017;7(1):9500.
   PubMedGoogle Scholar
• Byrn RA, Jones SM, Bennett HB, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother. 2015;59(3):1569–1582.
   PubMed Web of Science ®Google Scholar
• Feng E, Shin WJ, Zhu X, et al. Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors. J Med Chem. 2013;56(3):671–684.
   PubMed Web of Science ®Google Scholar
• Chou KC. Structural bioinformatics and its impact to biomedical science. Curr Med Chem. 2004;11(16):2105–2134.
   PubMed Web of Science ®Google Scholar
• Chou KC, Watenpaugh KD, Heinrikson RL. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator. Biochem Biophys Res Commun. 1999;259(2):420–428.
   PubMed Web of Science ®Google Scholar
• Huang RB, Du QS, Wang CH, et al. An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. Biochem Biophys Res Commun. 2008;377(4):1243–1247.
   PubMed Web of Science ®Google Scholar
• Chou KC. Insights from modelling the 3D structure of the extracellular domain of alpha7 nicotinic acetylcholine receptor. Biochem Biophys Res Commun. 2004;319(2):433–438.
   PubMed Web of Science ®Google Scholar
• Chou KC, Wei DQ, Zhong WZ. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun. 2003;308(1):148–151.
   PubMed Web of Science ®Google Scholar
• Chou KC, Tomasselli AG, Heinrikson RL. Prediction of the tertiary structure of a caspase-9/inhibitor complex. FEBS Lett. 2000;470(3):249–256.
   PubMed Web of Science ®Google Scholar
• Chou KC, Jones D, Heinrikson RL. Prediction of the tertiary structure and substrate binding site of caspase-8. FEBS Lett. 1997;419(1):49–54.
   PubMed Web of Science ®Google Scholar
• Li XB, Wang SQ, Xu WR, et al. Novel inhibitor design for hemagglutinin against H1N1 influenza virus by core hopping method. PLoS One. 2011;6(11):e28111.
   PubMed Web of Science ®Google Scholar
• Wang SQ, Du QS, Chou KC. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem Biophys Res Commun. 2007;354(3):634–640.
   PubMed Web of Science ®Google Scholar
• Pautus S, Sehr P, Lewis J, et al. New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain. J Med Chem. 2013;56(21):8915–8930.
   PubMed Web of Science ®Google Scholar
• Yuan S, Chu H, Singh K, et al. A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase. Sci Rep. 2016;6:22880.
   PubMed Web of Science ®Google Scholar
• Severson WE, McDowell M, Ananthan S, et al. High-throughput screening of a 100,000-compound library for inhibitors of influenza A virus (H3N2). J Biomol Screen. 2008;13(9):879–887.
   PubMed Web of Science ®Google Scholar
• Shin WJ, Lee KH, Park MH, et al. Broad-spectrum antiviral effect of agrimonia pilosa extract on influenza viruses. Microbiol Immunol. 2010;54(1):11–19.
   PubMed Web of Science ®Google Scholar
• Shin WJ, Nam KY, Kim ND, et al. Identification of a small benzamide inhibitor of influenza virus using a cell-based screening. Chemotherapy. 2016;61(3):159–166.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4(2):67–73.
   PubMed Web of Science ®Google Scholar
• Acharya R, Carnevale V, Fiorin G, et al. Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus. Proc Natl Acad Sci USA. 2010;107(34):15075–15080.
   PubMed Web of Science ®Google Scholar
• Pielak RM, Schnell JR, Chou JJ. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci USA. 2009;106(18):7379–7384.
   PubMed Web of Science ®Google Scholar
• Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis. 2007;196(2):249–257.
   PubMed Web of Science ®Google Scholar
• Dong J, Chen S, Li R, et al. Imidazole-based pinanamine derivatives: discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus. Eur J Med Chem. 2016;108:605–615.
   PubMed Web of Science ®Google Scholar
• Wang J, Wu Y, Ma C, et al. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc Natl Acad Sci USA. 2013;110(4):1315–1320.
   PubMed Web of Science ®Google Scholar
• Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 1994;3(10):1687–1696.
   PubMed Web of Science ®Google Scholar
• Taylor NR, von Itzstein M. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J Med Chem. 1994;37(5):616–624.
   PubMed Web of Science ®Google Scholar
• Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 1983;303(5912):41–44.
   PubMed Web of Science ®Google Scholar
• Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 1997;119(4):681–690.
   PubMed Web of Science ®Google Scholar
• Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010;65(Suppl 2):ii5–ii10.
   PubMed Web of Science ®Google Scholar
• Smee DF, Huffman JH, Morrison AC, et al. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother. 2001;45(3):743–748.
   PubMed Web of Science ®Google Scholar
• Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009;53(1):186–192.
   PubMed Web of Science ®Google Scholar
• Koyama K, Takahashi M, Oitate M, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother. 2009;53(11):4845–4851.
   PubMed Web of Science ®Google Scholar
• Collins PJ, Haire LF, Lin YP, et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature. 2008;453(7199):1258–1261.
   PubMed Web of Science ®Google Scholar
• Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001;45(12):3403–3408.
   PubMed Web of Science ®Google Scholar
• Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem. 2000;43(19):3482–3486.
   PubMed Web of Science ®Google Scholar
• Wu NC, Young AP, Dandekar S, et al. Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening. J Virol. 2013;87(2):1193–1199.
   PubMed Web of Science ®Google Scholar
• Trebbien R, Pedersen SS, Vorborg K, et al. Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014. Euro Surveill. 2017;22:3.
   Google Scholar
• Abed Y, Boivin G. A review of clinical influenza A and B infections with reduced susceptibility to both oseltamivir and zanamivir. Open Forum Infect Dis. 2017;4(3):ofx105.
   PubMed Web of Science ®Google Scholar
• Gubareva LV, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015–2016. Antiviral Res. 2017;146:12–20.
   PubMed Web of Science ®Google Scholar
• Li Q, Qi J, Zhang W, et al. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol. 2010;17(10):1266–1268.
   PubMed Web of Science ®Google Scholar
• Amaro RE, Minh DD, Cheng LS, et al. Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J Am Chem Soc. 2007;129(25):7764–7765.
   PubMed Web of Science ®Google Scholar
• Wu Y, Qin G, Gao F, et al. Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding. Sci Rep. 2013;3:1551.
   PubMed Web of Science ®Google Scholar
• Rudrawar S, Dyason JC, Rameix-Welti MA, et al. Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat Commun. 2010;1:113.
   PubMed Web of Science ®Google Scholar
• Wu Y, Vavricka CJ, Wu Y, et al. Atypical group 1 neuraminidase pH1N1-N1 bound to a group 1 inhibitor. Protein Cell. 2015;6(10):771–773.
   PubMed Web of Science ®Google Scholar
• Shie JJ, Fang JM, Wang SY, et al. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J Am Chem Soc. 2007;129(39):11892–11893.
   PubMed Web of Science ®Google Scholar
• Kim JH, Resende R, Wennekes T, et al. Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity. Science. 2013;340(6128):71–75.
   PubMed Web of Science ®Google Scholar
• Ye D, Shin WJ, Li N, et al. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities. Eur J Med Chem. 2012;54:764–770.
   PubMed Web of Science ®Google Scholar
• Te Velthuis AJW, Robb NC, Kapanidis AN, et al. The role of the priming loop in influenza A virus RNA synthesis. Nat Microbiol. 2016;1:16029.
   Web of Science ®Google Scholar
• Reich S, Guilligay D, Pflug A, et al. Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature. 2014;516(7531):361–366.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46(4):977–981.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005;49(3):981–986.
   PubMed Web of Science ®Google Scholar
• Pflug A, Guilligay D, Reich S, et al. Structure of influenza A polymerase bound to the viral RNA promoter. Nature. 2014;516(7531):355–360.
   PubMed Web of Science ®Google Scholar
• Yuan P, Bartlam M, Lou Z, et al. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature. 2009;458(7240):909–913.
   PubMed Web of Science ®Google Scholar
• Dias A, Bouvier D, Crepin T, et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature. 2009;458(7240):914–918.
   PubMed Web of Science ®Google Scholar
• Guilligay D, Tarendeau F, Resa-Infante P, et al. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol. 2008;15(5):500–506.
   PubMed Web of Science ®Google Scholar
• Fechter P, Mingay L, Sharps J, et al. Two aromatic residues in the PB2 subunit of influenza A RNA polymerase are crucial for cap binding. J Biol Chem. 2003;278(22):20381–20388.
   PubMed Web of Science ®Google Scholar
• Marcotrigiano J, Gingras AC, Sonenberg N, et al. Cocrystal structure of the messenger RNA 5ʹ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell. 1997;89(6):951–961.
   PubMed Web of Science ®Google Scholar
• Clark MP, Ledeboer MW, Davies I, et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem. 2014;57(15):6668–6678.
   PubMed Web of Science ®Google Scholar
• Bandarage UK, Clark MP, Perola E, et al. Novel 2-substituted 7-azaindole and 7-azaindazole analogues as potential antiviral agents for the treatment of influenza. ACS Med Chem Lett. 2017;8(2):261–265.
   PubMed Web of Science ®Google Scholar
• Farmer LJ, Clark MP, Boyd MJ, et al. Discovery of novel, orally bioavailable beta-amino acid azaindole inhibitors of influenza PB2. ACS Med Chem Lett. 2017;8(2):256–260.
   PubMed Web of Science ®Google Scholar
• Heo YA. Baloxavir: first global approval. Drugs. 2018;78(6):693–697.
   PubMed Web of Science ®Google Scholar
• Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018;160:109–117.
   PubMed Web of Science ®Google Scholar
• Boivin S, Cusack S, Ruigrok RW, et al. Influenza A virus polymerase: structural insights into replication and host adaptation mechanisms. J Biol Chem. 2010;285(37):28411–28417.
   PubMed Web of Science ®Google Scholar
• Obayashi E, Yoshida H, Kawai F, et al. The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature. 2008;454(7208):1127–1131.
   PubMed Web of Science ®Google Scholar
• Sugiyama K, Obayashi E, Kawaguchi A, et al. Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. Embo J. 2009;28(12):1803–1811.
   PubMed Web of Science ®Google Scholar
• Muratore G, Goracci L, Mercorelli B, et al. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci USA. 2012;109(16):6247–6252.
   PubMed Web of Science ®Google Scholar
• Yuan S, Chu H, Zhao H, et al. Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase. Antiviral Res. 2016;125:34–42.
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu Y, Foley C, et al. Exploring ugi-azide four-component reaction products for broad-spectrum influenza antivirals with a high genetic barrier to drug resistance. Sci Rep. 2018;8(1):4653.
   PubMedGoogle Scholar
• Yuan S, Chu H, Ye J, et al. Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface. Antiviral Res. 2017;137:58–66.
   PubMed Web of Science ®Google Scholar
• Jang YH, Seong BL. Options and obstacles for designing a universal influenza vaccine. Viruses. 2014;6(8):3159–3180.
   PubMed Web of Science ®Google Scholar
• Shin WJ, Seong BL. Type II transmembrane serine proteases as potential target for anti-influenza drug discovery. Expert Opin Drug Discov. 2017;12(11):1139–1152.
   PubMed Web of Science ®Google Scholar
• Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci USA. 2017;114(2):206–214.
   PubMed Web of Science ®Google Scholar
• Teissier E, Zandomeneghi G, Loquet A, et al. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One. 2011;6(1):e15874.
   PubMed Web of Science ®Google Scholar
• Leneva IA, Russell RJ, Boriskin YS, et al. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009;81(2):132–140.
   PubMed Web of Science ®Google Scholar
• Bodian DL, Yamasaki RB, Buswell RL, et al. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry. 1993;32(12):2967–2978.
   PubMed Web of Science ®Google Scholar
• Russell RJ, Kerry PS, Stevens DJ, et al. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci USA. 2008;105(46):17736–17741.
   PubMed Web of Science ®Google Scholar
• Basu A, Komazin-Meredith G, McCarthy C, et al. Molecular mechanism underlying the action of influenza A virus fusion inhibitor MBX2546. ACS Infect Dis. 2017;3(5):330–335.
   PubMed Web of Science ®Google Scholar
• Liu S, Li R, Zhang R, et al. CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entry. Eur J Pharmacol. 2011;660(2–3):460–467.
   PubMed Web of Science ®Google Scholar
• Chen X, Si L, Liu D, et al. Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin. Eur J Med Chem. 2015;93:182–195.
   PubMed Web of Science ®Google Scholar
• Hosoya M, Shigeta S, Ishii T, et al. Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo. J Infect Dis. 1993;168(3):641–646.
   PubMed Web of Science ®Google Scholar
• Bottcher-Friebertshauser E, Lu Y, Meyer D, et al. Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections. Vaccine. 2012;30(51):7374–7380.
   PubMed Web of Science ®Google Scholar
• Bahgat MM, Blazejewska P, Schughart K. Inhibition of lung serine proteases in mice: a potentially new approach to control influenza infection. Virol J. 2011;8:27.
   PubMed Web of Science ®Google Scholar
• Rossignol JF, La Frazia S, Chiappa L, et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem. 2009;284(43):29798–29808.
   PubMed Web of Science ®Google Scholar
• Belardo G, Cenciarelli O, La Frazia S, et al. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Antimicrob Agents Chemother. 2015;59(2):1061–1069.
   PubMed Web of Science ®Google Scholar
• Cianci C, Gerritz SW, Deminie C, et al. Influenza nucleoprotein: promising target for antiviral chemotherapy. Antivir Chem Chemother. 2012;23(3):77–91.
   PubMedGoogle Scholar
• Kao RY, Yang D, Lau LS, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol. 2010;28(6):600–605.
   PubMed Web of Science ®Google Scholar
• Gerritz SW, Cianci C, Kim S, et al. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci USA. 2011;108(37):15366–15371.
   PubMed Web of Science ®Google Scholar
• Perwitasari O, Johnson S, Yan X, et al. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo. J Virol. 2014;88(17):10228–10243.
   PubMed Web of Science ®Google Scholar
• White KM, Abreu P Jr., Wang H, et al. Broad spectrum inhibitor of influenza A and B viruses targeting the viral nucleoprotein. ACS Infect Dis. 2018;4(2):146–157.
   PubMed Web of Science ®Google Scholar
• Maxwell SR. Tamiflu and neuropsychiatric disturbance in adolescents. BMJ. 2007;334(7606):1232–1233.
   PubMedGoogle Scholar
• Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol. 2011;1(6):563–573.
   PubMed Web of Science ®Google Scholar
• Hama R, Bennett CL. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Acta Neurol Scand. 2017;135(2):148–160.
   PubMed Web of Science ®Google Scholar
• Hama R. Oseltamivir’s adverse reactions: fifty sudden deaths may be related to central suppression. BMJ. 2007;335(7610):59.
   PubMedGoogle Scholar
• Karlas A, Machuy N, Shin Y, et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature. 2010;463(7282):818–822.
   PubMed Web of Science ®Google Scholar
• Konig R, Stertz S, Zhou Y, et al. Human host factors required for influenza virus replication. Nature. 2010;463(7282):813–817.
   PubMed Web of Science ®Google Scholar
• Hao L, Sakurai A, Watanabe T, et al. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature. 2008;454:890.
   PubMed Web of Science ®Google Scholar
• Chen HW, Cheng JX, Liu MT, et al. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses. Antiviral Res. 2013;99(3):371–382.
   PubMed Web of Science ®Google Scholar
• Zhang L, Das P, Schmolke M, et al. Inhibition of pyrimidine synthesis reverses viral virulence factor-mediated block of mRNA nuclear export. J Cell Biol. 2012;196(3):315–326.
   PubMed Web of Science ®Google Scholar
• Kumar N, Sharma NR, Ly H, et al. Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses. Antimicrob Agents Chemother. 2011;55(12):5553–5559.
   PubMed Web of Science ®Google Scholar
• Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017;11(3):240–246.
   PubMed Web of Science ®Google Scholar